NCT07223424 2026-04-16
PSI-Immune
University of Pittsburgh
Phase 2 Recruiting
Clinical Trials
107 trialsNCT03304639 2026-04-13
Testing the Addition of Radiation Therapy to Immunotherapy for Merkel Cell Carcinoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT04708418 2026-04-13
A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05913388 2026-04-13
GB1211 and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
Providence Health & Services
Phase 2 Recruiting
NCT06961006 2026-04-13
INTerpath-012
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT04869137 2026-04-08
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT06099782 2026-04-08
MK-3475A-F11
Merck Sharp & Dohme LLC
Phase 2 Active not recruiting
NCT06984328 2026-04-08
Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizumab to Treat Advanced Melanoma of the Skin That Has Returned After Treatment With an Approved Checkpoint Inhibitor Therapy (ABBIL1TY MELANOMA-07)
Genmab
Phase 2 Active not recruiting
NCT02816021 2026-04-06
Study of Oral Azacitidine (CC-486) in Combination With Pembrolizumab (MK-3475) in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02621021 2026-04-01
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT05524935 2026-04-01
Olaparib in Combination With Pembrolizumab for Advanced Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT03620019 2026-03-27
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT04074096 2026-03-25
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
NCT04609566 2026-03-16
Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors
Seagen Inc.
Phase 2 Completed
NCT06771544 2026-03-10
Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma
University of California, Irvine
Phase 2 Recruiting
NCT05926960 2026-03-09
PORTSIDE
Pfizer
Phase 2 Terminated
NCT07448831 2026-03-09
NeoSenti
Universitair Ziekenhuis Brussel
Phase 2 Recruiting
NCT06999980 2026-02-19
Neo IRENIE
Melanoma Institute Australia
Phase 2 Recruiting
NCT05496036 2026-02-18
MCC
Abramson Cancer Center at Penn Medicine
Phase 2 Recruiting
NCT05155033 2026-02-17
Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT07376317 2026-01-29
OTIMAS
Instituto do Cancer do Estado de São Paulo
Phase 2 Active not recruiting
NCT07349303 2026-01-21
NEOPRIME
Vastra Gotaland Region
Phase 2 Recruiting
NCT03228667 2026-01-14
QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
ImmunityBio, Inc.
Phase 2 Active not recruiting
NCT03873818 2026-01-09
Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain
M.D. Anderson Cancer Center
Phase 2 Completed
NCT05034536 2026-01-08
PD-1 Antibody Therapy + Infliximab for Metastatic Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT05956041 2026-01-07
Pembrolizumab and Mogamulizumab in Advanced-stage, Relapsed/Refractory Cutaneous T-cell Lymphomas
University of Michigan Rogel Cancer Center
Phase 2 Recruiting
NCT04207086 2025-12-16
Neo PeLe
Melanoma Institute Australia
Phase 2 Active not recruiting
NCT07283822 2025-12-16
Amping up With PemJAK
Columbia University
Phase 2 Recruiting
NCT03595683 2025-12-08
Pembrolizumab and EDP1503 in Advanced Melanoma
University of Chicago
Phase 2 Terminated
NCT03149029 2025-12-05
Abbreviated MAPK Targeted Therapy Plus Pembrolizumab in Melanoma
Massachusetts General Hospital
Phase 2 Active not recruiting
NCT03897881 2025-12-03
An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942)
ModernaTX, Inc.
Phase 2 Active not recruiting
NCT04570332 2025-11-26
SPOTLIGHT203
Highlight Therapeutics
Phase 2 Completed
NCT04955743 2025-11-24
Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma
Yale University
Phase 2 Terminated
NCT05282901 2025-11-24
PLUME
Institut Curie
Phase 2 Active not recruiting
NCT04796194 2025-11-20
ATLAS-IT-05
Lytix Biopharma AS
Phase 2 Completed
NCT02965716 2025-11-18
Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT05309421 2025-09-22
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma
Evaxion Biotech A/S
Phase 2 Active not recruiting
NCT06906822 2025-09-18
PlugIN
Grupo Español Multidisciplinar de Melanoma
Phase 2 Recruiting
NCT02681549 2025-08-07
Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC)
Yale University
Phase 2 Completed
NCT05308901 2025-07-25
Lenvatinib Plus Pembrolizumab In Patients With Immune Checkpoint Inhibitor Naïve Metastatic Uveal Melanoma
Providence Health & Services
Phase 2 Active not recruiting
NCT05304546 2025-07-22
MK3475-C01
Sheba Medical Center
Phase 2 Completed
NCT03645928 2025-06-19
LN-144
Iovance Biotherapeutics, Inc.
Phase 2 Recruiting
NCT02743819 2025-06-10
Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma
University of Chicago
Phase 2 Active not recruiting
NCT04830124 2025-06-10
ARTISTRY-6
Mural Oncology, Inc
Phase 2 Terminated
NCT05583708 2025-05-23
iPRRT
Weill Medical College of Cornell University
Phase 2 Recruiting
NCT04993677 2025-05-11
A Study of SEA-CD40 Given With Other Drugs in Cancers
Seagen Inc.
Phase 2 Completed
NCT06797297 2025-04-04
A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy
Innovent Biologics (Suzhou) Co. Ltd.
Phase 2 Recruiting
NCT02644369 2025-03-26
INSPIRE
University Health Network, Toronto
Phase 2 Active not recruiting
NCT05313243 2025-03-20
Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory T-cell Lymphoma
Yale University
Phase 2 Recruiting